ELISAs Instruments and Reagents Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

ELISAs Instruments and Reagents Market Overview

The ELISAs Instruments and Reagents Market is poised for significant growth from 2025 to 2030, driven by advancements in diagnostic technologies, increasing prevalence of chronic diseases, and rising demand for automated and high-throughput systems. The market is projected to grow at a CAGR of 5.8% during the forecast period, reaching a market size of $3.2 billion by 2030.

Market Size and Share Analysis

The global ELISAs instruments and reagents market was valued at $2.4 billion in 2025 and is expected to grow to $3.2 billion by 2030. The market is segmented by product type, process, application, end-use, and region.

By Product Type

• Instruments: The instruments segment accounted for 45% of the market share in 2025, with a projected growth rate of 6.2% CAGR from 2025 to 2030.
• Reagents: The reagents segment held 55% of the market share in 2025, with an expected growth rate of 5.5% CAGR during the forecast period.

By Key Players

The market is highly competitive, with key players including:

• Roche: Holding a market share of 18% in 2025.
• Abbott: Capturing 15% of the market in 2025.
• Danaher: With a market share of 12% in 2025.
• DiaSorin: Accounting for 10% of the market in 2025.
• Thermo Fisher Scientific: Holding 9% of the market in 2025.
• BioMrieux: With a market share of 8% in 2025.
• BD Biosciences: Capturing 7% of the market in 2025.
• Bio-Rad Laboratories: Accounting for 6% of the market in 2025.
• PerkinElmer: Holding 5% of the market in 2025.
• Agilent Technologies: With a market share of 4% in 2025.
• Bio-Techne: Capturing 3% of the market in 2025.
• Ortho-Clinical Diagnostics: Accounting for 2% of the market in 2025.
• Merck KGaA: Holding 1% of the market in 2025.
• Eurofins Scientific: With a market share of 1% in 2025.

By Process

The market is segmented into:

• Manual ELISAs: Accounting for 30% of the market in 2025.
• Automated ELISAs: Holding 70% of the market in 2025, with a projected growth rate of 6.5% CAGR from 2025 to 2030.

By Application

The market is segmented by application into:

• Hospitals: Accounting for 50% of the market in 2025.
• Clinics: Holding 30% of the market in 2025.
• Others: Including research laboratories and diagnostic centers, accounting for 20% of the market in 2025.

By End-Use

The market is segmented by end-use into:

• Diagnostic Laboratories: Accounting for 40% of the market in 2025.
• Pharmaceutical and Biotechnology Companies: Holding 35% of the market in 2025.
• Academic and Research Institutes: Accounting for 25% of the market in 2025.

By Region

The market is segmented by region into:

• North America: Accounting for 40% of the market in 2025, with a projected growth rate of 6.0% CAGR from 2025 to 2030.
• Europe: Holding 30% of the market in 2025, with an expected growth rate of 5.5% CAGR during the forecast period.
• Asia-Pacific: Accounting for 20% of the market in 2025, with a projected growth rate of 7.0% CAGR from 2025 to 2030.
• Latin America: Holding 5% of the market in 2025, with an expected growth rate of 5.0% CAGR during the forecast period.
• Middle East & Africa: Accounting for 5% of the market in 2025, with a projected growth rate of 4.5% CAGR from 2025 to 2030.

Market Trends

The ELISAs instruments and reagents market is witnessing several key trends:

• Increasing Adoption of Automated Systems: The demand for automated ELISAs systems is growing due to their ability to reduce human error and increase throughput.
• Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the demand for ELISAs-based diagnostics.
• Technological Advancements: Innovations in ELISAs technology, such as the development of multiplex assays, are enhancing the efficiency and accuracy of diagnostic tests.
• Growing Focus on Personalized Medicine: The shift towards personalized medicine is increasing the demand for ELISAs-based biomarkers for disease diagnosis and monitoring.

Market News on Policy and Companies

Recent developments in the ELISAs instruments and reagents market include:

• Regulatory Approvals: In 2025, Roche received FDA approval for its new automated ELISAs system, which is expected to significantly boost its market share.
• Strategic Collaborations: Abbott and DiaSorin announced a strategic partnership in 2025 to develop advanced ELISAs-based diagnostic solutions for infectious diseases.
• Mergers and Acquisitions: Thermo Fisher Scientific acquired Bio-Techne in 2025, strengthening its position in the ELISAs reagents market.
• Product Launches: Bio-Rad Laboratories launched a new line of high-sensitivity ELISAs reagents in 2025, targeting the growing demand for early disease detection.

Segment Forecasts 2025 - 2030

The ELISAs instruments and reagents market is expected to witness robust growth across all segments from 2025 to 2030:

• Instruments Segment: Projected to grow at a CAGR of 6.2%, reaching a market size of $1.5 billion by 2030.
• Reagents Segment: Expected to grow at a CAGR of 5.5%, reaching a market size of $1.7 billion by 2030.
• Automated ELISAs: Projected to grow at a CAGR of 6.5%, reaching a market size of $2.2 billion by 2030.
• Hospitals Segment: Expected to grow at a CAGR of 6.0%, reaching a market size of $1.6 billion by 2030.
• North America: Projected to grow at a CAGR of 6.0%, reaching a market size of $1.3 billion by 2030.

Conclusion

The ELISAs Instruments and Reagents Market is set for substantial growth from 2025 to 2030, driven by technological advancements, increasing demand for automated systems, and the rising prevalence of chronic diseases. Key players such as Roche, Abbott, and Danaher are expected to dominate the market, with significant contributions from emerging markets in Asia-Pacific. The market is projected to reach $3.2 billion by 2030, with a CAGR of 5.8% during the forecast period.